Evidence-Based Cardiovascular Risk Management in Diabetes

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Diabetes mellitus significantly increases cardiovascular disease (CVD) risk and mortality.
• Recent advancements in risk management have led to a decline in cardiovascular mortality among diabetic patients.
• Identifying and utilizing cardioprotective antihyperglycemic agents is crucial.

Purpose of the Study:

• To review current evidence-based strategies for cardiovascular risk management in diabetes.
• To highlight specific pharmacological agents with proven cardioprotective effects.
• To outline treatment goals for blood pressure, lipids, and antiplatelet therapy in diabetic patients.

Main Methods:

• Review of current clinical guidelines and landmark trials.
• Analysis of pharmacological interventions for glycemic control, lipid management, and blood pressure.
• Evaluation of the role of antiplatelet therapy, obesity management, and bariatric surgery.

Main Results:

• Several antihyperglycemic drugs (metformin, GLP-1 receptor agonists, SGLT2 inhibitors) demonstrate cardioprotective benefits.
• Statins are essential for patients with established or at-risk coronary artery disease (CAD).
• Targeted lipid-lowering with ezetimibe or PCSK9 inhibitors, ACE inhibitors/ARBs, and strict blood pressure control (<140/90 mmHg, or <130/80 mmHg in high-risk cases) are recommended.

Conclusions:

• A multipronged approach integrating pharmacotherapy, lifestyle modifications, and risk factor control is key to reducing cardiovascular mortality in diabetes.
• Treatment decisions should be individualized, considering patient preferences, affordability, side effect profiles, and evidence of cardiovascular benefit.
• Bariatric surgery offers significant benefits for quality of life and cardiovascular risk reduction in select obese diabetic patients.